Zobrazeno 1 - 10
of 680
pro vyhledávání: '"Thrombopoietin receptor agonist"'
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 4025-4036 (2024)
Ran Zhao,1,* Dexiang Ji,1,* Yulan Zhou,1,2 Ling Qi,1,2 Fei Li1,2 1Jiangxi Provincial Key Laboratory of Hematological Diseases, Department of Hematology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Ji
Externí odkaz:
https://doaj.org/article/9a6b759590c14d6f989a2d9f8f4837e4
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract With its increasing use in the treatment of thrombocytopenia, avatrombopag’s associated adverse events (AEs) pose a major challenge to its clinical application. This study aims to comprehensively study AEs associated with avatrombopag by u
Externí odkaz:
https://doaj.org/article/699978bc808a439496e8160d908048df
Autor:
S. G. Zakharov, T. A. Mitina, A. V. Zakharova, O. P. Madzyara, I. N. Kontievskii, R. V. Vardanyan, E. V. Kataeva, Yu. B. Chernykh, L. L. Vysotskaya, L. V. Ivanitskiy, Yu. Yu. Chuksina, O. R. Zhuravlev, N. V. Gorgun, Z. M. Kharasova, E. V. Trifonova, K. A. Belousov, Z. R. Tekeeva
Publikováno v:
Онкогематология, Vol 19, Iss 2, Pp 109-117 (2024)
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and decreased platelet production. The formation of antibodies to platelet and megakaryocyte glycoproteins plays a major role in the pathophysiolog
Externí odkaz:
https://doaj.org/article/30d95f9a80694e7ca526cd07cc2bf0e3
Autor:
Alaa Rahhal, Drew Provan, Waleed Ghanima, Tomás José González-López, Khaled Shunnar, Mostafa Najim, Ashraf Omer Ahmed, Waail Rozi, Abdulrahman Arabi, Mohamed Yassin
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
IntroductionImmune thrombocytopenia (ITP) management with co-existing acute coronary syndrome (ACS) remains challenging as it requires a clinically relevant balance between the risk and outcomes of thrombosis and the risk of bleeding. However, the li
Externí odkaz:
https://doaj.org/article/990da78dd7154f2db6bb4a59d74c6cbf
Autor:
Pedro Marques Ramos, Jeea Choi, Catarina D. Campbell, Ying A. Wang, Celine Pallaud, Michael Dickinson, Amit Verma, Moshe Mittelman, Uwe Platzbecker, Honar Cherif, Pierre Fenaux
Publikováno v:
eJHaem, Vol 4, Iss 3, Pp 876-881 (2023)
Abstract Eltrombopag has been previously shown to be effective in reversing azacitidine‐mediated thrombocytopenia. This was further investigated in the SUPPORT trial, a phase III study assessing the efficacy/safety of eltrombopag plus azacitidine i
Externí odkaz:
https://doaj.org/article/1a4eb4e4b59b4fa7b1cc250080b778b7
Autor:
Valérian Rivet, Vincent Sibaud, Jérémie Dion, Thibaut Volosov, Mélanie Biteau, Andréa Pastissier, Karen Delavigne, Pierre Cougoul, Odile Rauzy, Thibault Comont
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionImmune checkpoint inhibitors (ICIs) are used in several advanced malignancies and may cause various immune-related adverse events (irAEs). Among them, hematological irAEs are less described. Acquired amegakaryocytic thrombocytopenia (AAT)
Externí odkaz:
https://doaj.org/article/bba72c905eee4b4facc38b47d1aad356
Autor:
Emilie J. Lynch, Autumn Citta, Constance Alford, John A. Ligon, Mansi Dalal, Paul Castillo, Biljana Horn, Natalie Dotson, Giselle Moore-Higgs, Jordan Milner
Publikováno v:
Leukemia Research Reports, Vol 22, Iss , Pp 100472- (2024)
Patients who receive allogeneic hematopoietic stem cell transplantation (alloHSCT) are at risk for developing persistent thrombocytopenia. Here, we describe treatment with avatrombopag, a thrombopoietin receptor agonist, in a pediatric patient with c
Externí odkaz:
https://doaj.org/article/c0c4899820df420ea9a64953e8ed8546
Publikováno v:
Heliyon, Vol 10, Iss 1, Pp e24051- (2024)
Background: Thrombopoietin receptor agonists (TPO-RAs) have been widely used to treat thrombocytopenia, however, a scientometric profile of TPO-RAs research is lacking. Methods: This study uses VOSviewer, CiteSpace, and R software to provide an overv
Externí odkaz:
https://doaj.org/article/a876cc232c1f48b192aee93bdb01a389
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mohamed A. Yassin, Mona Al-Rasheed, Murtadha Al-Khaboori, Mahmoud Marashi, Hani Osman, Yasser Wali, Salam Al Kindi, Faisal Alsayegh, Drew Provan
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
IntroductionThrombopoietin-receptor agonist (TPO-RAs) currently represent the state of art for treating immune thrombocytopenia. Their different molecular structures contribute to the difference in their pharmacodynamics and pharmacokinetics. This na
Externí odkaz:
https://doaj.org/article/4f6a087b656b418f86cf0903c7502c43